The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11100023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pemphigus vulgaris is an autoimmune blistering disease for which the mainstay of treatment is systemic corticosteroids and immunosuppressants. This therapy had reduced the mortality of pemphigus; however, it is associated with significant morbidity. The objective of this study was to assess the group's experience with plasmapheresis in the treatment of pemphigus vulgaris and report on its utility. Seven patients with severe or resistant pemphigus vulgaris underwent a series of 5 plasma exchanges over an average of 8 days. Immunosuppressive drugs were administered immediately after plasmapheresis to prevent the "rebound" flare of disease that can occur after plasmapheresis. Remission was induced in 4 patients, partial remission was induced in 2 patients, and 1 patient continues to have active disease. This study suggests that plasmapheresis is a useful intervention in patients with pemphigus vulgaris who are not responding to standard therapy or who require unacceptably high doses of steroids or immunosuppressants.
Medical subject headings
- Immunosuppressive Agents
- Immunotherapy
- Pemphigus
- Plasmapheresis